🔗Orphan Drug Savings: Is Your Hospital Leaving Money on the Table?
Orphan drug savings often sit unclaimed inside a hospital's own purchasing data. Many facilities assume every orphan designated drug falls outside 340B pricing, yet that assumption costs real money every quarter. Some drugs qualify through manufacturer discretionary pricing even when the mandatory 340B discount does not apply.
Hospitals that actively track orphan drug savings tend to follow a few clear habits.
-
They review their drug purchasing list on a regular schedule
-
They separate orphan drugs used for a rare condition from the same drug used for a common one
-
They track which manufacturers currently offer voluntary discounts
-
They document every purchase carefully to stay audit-ready
Skipping these steps means a hospital pays full price for drugs that may already qualify for meaningful savings. Rural and safety net hospitals feel this gap the most, since every dollar affects staffing, equipment, and patient services directly across the organization.
Dr. Lisa Nezneski, PharmD, BCPS, has spent more than a decade focused exclusively on orphan drug savings. Her team at 340B Orphan Drug Solutions has helped hospitals nationwide capture more than 500 million dollars through this exact process. The service builds a custom drug list for each facility, integrates with existing split billing software, and updates the list quarterly as manufacturer pricing shifts.
Your hospital may already qualify for savings you have not identified yet. Schedule a compliance review with 340B Orphan Drug Solutions today and find out exactly where your orphan drug savings are hiding this quarter.
- Art
- Causes
- Crafts
- Dance
- Drinks
- Film
- Fitness
- Food
- Игры
- Gardening
- Health
- Главная
- Literature
- Music
- Networking
- Другое
- Party
- Religion
- Shopping
- Sports
- Theater
- Wellness